Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.
Details : Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Product Name : Iyuzeh
Product Type : HPAPI
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Product Name : Iyuzeh
Product Type : HPAPI
Upfront Cash : Inapplicable
March 03, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IYUZEH™ is the first and only clinically proven formulation of latanoprost available in the United States that is preservative-free. IYUZEH™ is formulated without any of the preservatives commonly used in topical ocular preparations, including benzal...
Product Name : Iyuzeh
Product Type : HPAPI
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable